P R S Lagacé-Wiens1,2, H J Adam1,2, N M Laing1, M R Baxter1, I Martin3, M R Mulvey1,3, J A Karlowsky1,2, D J Hoban1,2, G G Zhanel1. 1. Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, 771 Bannatyne Ave., Winnipeg, Manitoba, Canada, R3E 3N4. 2. Department of Clinical Microbiology, Diagnostic Services Manitoba, L4025-409 Taché Ave., Winnipeg, Manitoba, Canada, R2H 2A6. 3. Streptococcus and STI Unit, National Microbiology Laboratory, 1015 Arlington St., Winnipeg, Manitoba, Canada, R3E 3R2.
Abstract
Background: The prevalence of MDR Neisseria gonorrhoeae is increasing globally and represents a public health emergency. Development and approval of new anti-gonococcal agents may take years. As a concurrent approach to developing new antimicrobials, the laboratory and clinical evaluation of currently licensed antimicrobials not widely used for the treatment of gonorrhoea may provide new options for the treatment of gonococcal infections. Objectives: To determine the in vitro activity of nine alternative, currently licensed and late-development antimicrobials with the potential to treat gonococcal infections against 112 clinical isolates of N. gonorrhoeae resistant to one or multiple antimicrobials. Methods: The MICs of conventional anti-gonococcal antimicrobials (penicillin, ceftriaxone, cefixime, azithromycin, ciprofloxacin, tetracycline and spectinomycin) and alternative antimicrobials (ertapenem, gentamicin, netilmicin, tigecycline, eravacycline, fosfomycin, linezolid, ceftazidime/avibactam and ceftaroline) were determined by agar dilution. Results: Ertapenem and the novel cephalosporins demonstrated similar MIC values to the third-generation cephalosporins, but increased MICs were observed for isolates with increased cefixime and ceftriaxone MICs. Tigecycline and eravacycline had MIC values below expected serum concentrations for all isolates tested. The aminoglycosides gentamicin and netilmicin were generally more potent than spectinomycin, with netilmicin demonstrating the greatest potency. Fosfomycin MICs were elevated compared with other agents, but remained within the MIC range for susceptible organisms, while linezolid MICs were generally higher than those for organisms considered resistant. Conclusions: Among potentially therapeutically useful alternative agents, the aminoglycosides, eravacycline, tigecycline and fosfomycin had good in vitro activity. The novel cephalosporins and ertapenem had comparable activity to cefixime and ceftriaxone.
Background: The prevalence of MDR Neisseria gonorrhoeae is increasing globally and represents a public health emergency. Development and approval of new anti-gonococcal agents may take years. As a concurrent approach to developing new antimicrobials, the laboratory and clinical evaluation of currently licensed antimicrobials not widely used for the treatment of gonorrhoea may provide new options for the treatment of gonococcal infections. Objectives: To determine the in vitro activity of nine alternative, currently licensed and late-development antimicrobials with the potential to treat gonococcal infections against 112 clinical isolates of N. gonorrhoeae resistant to one or multiple antimicrobials. Methods: The MICs of conventional anti-gonococcal antimicrobials (penicillin, ceftriaxone, cefixime, azithromycin, ciprofloxacin, tetracycline and spectinomycin) and alternative antimicrobials (ertapenem, gentamicin, netilmicin, tigecycline, eravacycline, fosfomycin, linezolid, ceftazidime/avibactam and ceftaroline) were determined by agar dilution. Results:Ertapenem and the novel cephalosporins demonstrated similar MIC values to the third-generation cephalosporins, but increased MICs were observed for isolates with increased cefixime and ceftriaxone MICs. Tigecycline and eravacycline had MIC values below expected serum concentrations for all isolates tested. The aminoglycosidesgentamicin and netilmicin were generally more potent than spectinomycin, with netilmicin demonstrating the greatest potency. Fosfomycin MICs were elevated compared with other agents, but remained within the MIC range for susceptible organisms, while linezolid MICs were generally higher than those for organisms considered resistant. Conclusions: Among potentially therapeutically useful alternative agents, the aminoglycosides, eravacycline, tigecycline and fosfomycin had good in vitro activity. The novel cephalosporins and ertapenem had comparable activity to cefixime and ceftriaxone.
Authors: Stefan Riedel; Divya Vijayakumar; Gretchen Berg; Anthony D Kang; Kenneth P Smith; James E Kirby Journal: J Antimicrob Chemother Date: 2019-05-01 Impact factor: 5.790
Authors: Ian Morrissey; Stephen Hawser; Sibylle H Lob; James A Karlowsky; Matteo Bassetti; G Ralph Corey; Melanie Olesky; Joseph Newman; Corey Fyfe Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191
Authors: Ian Morrissey; Melanie Olesky; Stephen Hawser; Sibylle H Lob; James A Karlowsky; G Ralph Corey; Matteo Bassetti; Corey Fyfe Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191